ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2366

Economic Impact Of Adalimumab Treatment In Japanese Patients With Rheumatoid Arthritis: Analysis Of 24 Weeks Data From The Anouveau Study

Yoshiya Tanaka1, Yasuhiko Shinmura2, Ryo Nakajima2, Takahiro Muramatsu2, Shuichi Komatsu3, Tadamichi Kubo2, Aki Kuroki4, Ataru Igarashi5, Toshiro Tango6 and Tsutomu Takeuchi7, 1The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2Post Marketing Study Group, Medical, AbbVie GK, Tokyo, Japan, 3Scientific Project Manager Group, Medical, AbbVie GK, Tokyo, Japan, 4Medical Affairs, AbbVie GK, Tokyo, Japan, 5Department of Drug Policy & Management, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan, 6Center for Medical Statistics, Tokyo, Japan, 7Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Adalimumab, economics and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy III

Session Type: Abstract Submissions (ACR)

Background/Purpose: Patients with rheumatoid arthritis (RA) incur higher costs owing to missed work days and short-time disability. Although methotrexate combined with adalimumab (ADA) provides comprehensive disease control in patients with RA, its impact in aspect of economic burden is less well understood. The purpose of this study is to assess the economic benefit of ADA treatment in Japanese patients with RA.

Methods: Data were taken from the first 24 weeks of a 48-week, multicenter, prospective, single-cohort study of self-reported work productivity and activity impairment in 512 Japanese patients with RA receiving ADA. Work-related outcomes were measured using the Work Productivity and Activity Impairment questionnaire for rheumatoid arthritis (WPAI/RA), including employment status (paid worker [PW] employed for ≥35hours/week, n=160, part time worker [PTW] employed for <35hours/week, n=80, or home worker [HW] non-employed, n=272), absenteeism (percentage of work time missed due to RA), presenteeism (percentage of impairment while working due to RA), percentage of overall work impairment (OWI) due to RA, and percentage of activity impairment (AI) due to RA. The Health Assessment Questionnaire-Disability Index (HAQ-DI), EuroQol-5Dimensions (EQ-5D), and disease activity score based on 28 joints count erythrocyte sedimentation rate (DAS28 ESR) were used to assess clinical response. Annually productivity loss was estimated using WPAI/RA scores and basic wages in Japanese workers 2012 by the Ministry of Health, Labor and Welfare.

Results: At week 24, disease activity measures were significantly improved. There were significant improvements in presenteeism of PWs and PTWs, in OWI of PWs, and in AI of all employment status. Changes in WPAI/RA domain scores correlated strongly with measures of clinical response. The saved productivity losses due to OWI and AI through week 24 were 7,400 USD for PWs, 1,300 USD for PTWs, and 4,700 USD for HWs. Improvements 2 in DAS28 ESR score, 0.5 in HAQ-DI score, and 0.2 in EQ-5D through one year were estimated to save 10,000 USD annually from productivity loss due to OWI in PWs (1 USD = 100 JPY in 2013).

Conclusion: ADA treatment reduced indirect cost due to work impairment in Japanese RA patients in different employment status.


Disclosure:

Y. Tanaka,

BMS, MSD, Chugai, Mitsubishi-Tanabe, Astellas, Abbvie, Daiichi-Sankyo,

2,

Mitsubishi-Tanabe, Abbott, Abbvie, Eisai, Chugai, Janssen, Pfizer, Takeda, Astellas, Daiichi-Sankyo, GSK, AstraZeneca, Eli Lilly, Quintiles, MSD, Asahi Kasei,

8,

Mitsubishi-Tanabe, Abbott, Abbvie, Eisai, Chugai, Janssen, Pfizer, Takeda, Astellas, Daiichi-Sankyo, GSK, AstraZeneca, Eli Lilly, Quintiles, MSD, Asahi Kasei,

5;

Y. Shinmura,

AbbVie GK,

3;

R. Nakajima,

AbbVie GK,

3;

T. Muramatsu,

AbbVie GK,

3;

S. Komatsu,

AbbVie GK,

3;

T. Kubo,

AbbVie GK,

3;

A. Kuroki,

AbbVie GK,

3;

A. Igarashi,

Abbvie GK., Abbott Japan Co., Ltd., Boehringer Ingelheim Japan, Inc., Novartis Pharma K.K., and Pfizer Japan Inc.,

5,

TOWA Pharmaceutical Co., Ltd.,

9;

T. Tango,

AbbVie GK., Ajinomoto Pharma, Hospira Japan Co., Ltd.,

5;

T. Takeuchi,

Astra Zeneca K.K., Eli Lilly Japan K.K., Novartis Pharma K.K., Mitsubishi Tanabe Pharma Co., and Asahi Kasei Medical K.K,

5,

AbbVie GK., Bristol–Myers K.K., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., and Takeda Pharmaceutical Co., Ltd.,

8,

AbbVie GK., Astellas Pharma, Bristol–Myers K.K., Chugai Pharmaceutical Co, Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Nippon Shinyaku Co., Ltd., Pfizer Japan Inc., Sanofi–Aventis K.K.,

2,

Santen Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd.,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/economic-impact-of-adalimumab-treatment-in-japanese-patients-with-rheumatoid-arthritis-analysis-of-24-weeks-data-from-the-anouveau-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology